The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting and Change of Name

18 Apr 2016 12:41

RNS Number : 5212V
Fastnet Equity PLC
18 April 2016
 

Fastnet Equity plc

 

("Fastnet" or the "Company")

 

Result of General Meeting and Change of Name

 

18 April 2016, London - Further to the announcement on 31 March 2016 in relation to the Proposals, the Directors are pleased to announce that all resolutions proposed at the General Meeting of the Company held earlier today were approved. Consequently the Acquisition will now proceed and accordingly the Company's name will change to Amryt Pharma plc ("Amryt"). Following the change of name, the Company's ticker will change to 'AMYT' on AIM and 'AYP' on the ESM.

 

Following the Capital Reorganisation, the Company's ISIN and SEDOL will change to GB00BDD1LS57 and BDD1LS5, respectively. It is expected that the New Ordinary Shares arising as a result of the Capital Reorganisation in respect of Existing Ordinary Shares held in uncertificated form, i.e. in CREST, will be credited to the relevant CREST accounts on 19 April 2016.

 

Trading on AIM and the ESM of the Existing Ordinary Shares of the Company will be cancelled, and re-admission and dealings in New Ordinary Shares in Amryt will commence on AIM and ESM, at 8.00 a.m. on 19 April 2016.

 

Terms used in this announcement shall have the meanings given to them in the Company's admission document dated 31 March 2016.

 

The Admission Document is available on the Company's website www.amrytpharma.com

 

For further information, please contact:

 

Amryt Pharma plc

C/o FTI Consulting

Joe Wiley, CEO

Rory Nealon, CFO/COO

Shore Capital

+44 (0) 20 7408 4090

Nomad and Joint Broker

Bidhi Bhoma, Edward Mansfield

Davy

+353 (1) 679 6363

ESM Adviser and Joint Broker

John Frain, Anthony Farrell

Stifel

+44 (0) 20 7710 7600

Joint Broker

Jonathan Senior, Ben Maddison

FTI Consulting

+44 (0) 20 3727 1000

Simon Conway, Brett Pollard

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCAKFDKDBKDNQD
Date   Source Headline
7th Jan 20197:00 amRNSPositive results for gene therapy AP103
4th Jan 201912:56 pmRNSEASE Phase III trial interim efficacy results
21st Dec 20182:05 pmRNSSecond Price Monitoring Extn
21st Dec 20182:00 pmRNSPrice Monitoring Extension
19th Dec 20187:00 amRNSUpdate on ongoing AP101 Trial
10th Dec 201811:30 amRNSGrant Funding from Irish Government for AP103
17th Oct 20187:00 amRNSLojuxta to be reimbursed in France
26th Sep 20187:00 amRNSInterim Results
14th Sep 20187:00 amRNSNotice of Results
10th Sep 20187:00 amRNSAmryt receives IND approval from FDA for AP101
2nd Aug 20187:00 amRNSFDA grants Pediatric Rare Disease designation
19th Jul 20187:00 amRNSTrading update & significant momentum building
9th Jul 20187:00 amRNSNHS England approves funding for Lojuxta
6th Jul 20187:00 amRNSChange of Registered Address
25th Jun 20188:10 amRNSCompany name alteration for previous release
25th Jun 20187:00 amRNSPositive data of Pollinex Quattro Grass vaccine
5th Jun 201810:41 amRNSResult of AGM
29th May 20187:00 amRNSFour Middle East Lojuxta® Distribution Agreements
10th May 20187:00 amRNSExclusive Lojuxta® Licence Expanded
9th May 20182:48 pmRNSHolding(s) in Company
8th May 20187:00 amRNSHolding(s) in Company and Lock-in agreement
4th May 20187:00 amRNSPosting of Annual Report 2017 and Notice of AGM
17th Apr 20187:00 amRNSFinal Results
15th Mar 20187:00 amRNSTrading update & Gene therapy agreement
6th Mar 20187:00 amRNSSenior Management Appointment
6th Mar 20187:00 amRNSDistribution Agreement for Lojuxta in Middle East
2nd Mar 20187:00 amRNSNotice of Trading Update
30th Jan 20187:00 amRNSNew Distribution Agreement Signed
24th Jan 20187:00 amRNSSenior Management Team Appointment
10th Jan 20187:00 amRNSNew Distribution Agreement Signed
8th Jan 20187:00 amRNSDistribution Agreement Signed Covering Switzerland
20th Dec 20177:00 amRNSSenior Management Team Appointment
1st Dec 20177:00 amRNSGrant of Options & PDMR Dealings
20th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20177:00 amRNSDistribution Agreement Signed in Saudi Arabia
13th Oct 20173:29 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirector Share Purchases
11th Oct 20177:00 amRNSHolding(s) in Company
11th Oct 20177:00 amRNSEnterprise Securities Market Notice
10th Oct 20177:00 amRNSEnterprise Securities Market Notice
9th Oct 201712:13 pmRNSResult of General Meeting & Completion of Placing
21st Sep 20177:00 amRNSPlacing to raise EUR 15m
4th Sep 20177:00 amRNSInterim Results
31st Aug 20177:00 amRNSAttendance at Rodman & Renshaw Conference
30th Aug 20177:00 amRNSSenior Management Appointment
23rd Aug 20178:30 amRNSNotice of Results
25th Jul 20177:00 amRNSHighly positive long-term study results - Lojuxta
25th May 201711:49 amRNSResult of AGM
25th May 20177:00 amRNSAGM Statement
27th Apr 20177:00 amRNSStudy Results of Real-World Experience of Lojuxta

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.